239 related articles for article (PubMed ID: 18408020)
1. Gene expression analysis of interferon-beta treatment in multiple sclerosis.
Sellebjerg F; Datta P; Larsen J; Rieneck K; Alsing I; Oturai A; Svejgaard A; Soelberg Sørensen P; Ryder LP
Mult Scler; 2008 Jun; 14(5):615-21. PubMed ID: 18408020
[TBL] [Abstract][Full Text] [Related]
2. Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing beta-interferon therapy.
Singh MK; Scott TF; LaFramboise WA; Hu FZ; Post JC; Ehrlich GD
J Neurol Sci; 2007 Jul; 258(1-2):52-9. PubMed ID: 17467740
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics of MXA SNPs in interferon-beta treated multiple sclerosis patients.
Weinstock-Guttman B; Tamaño-Blanco M; Bhasi K; Zivadinov R; Ramanathan M
J Neuroimmunol; 2007 Jan; 182(1-2):236-9. PubMed ID: 17126411
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis.
Hong J; Zang YC; Hutton G; Rivera VM; Zhang JZ
J Neuroimmunol; 2004 Jul; 152(1-2):126-39. PubMed ID: 15223245
[TBL] [Abstract][Full Text] [Related]
5. Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression.
Krakauer M; Sorensen P; Khademi M; Olsson T; Sellebjerg F
Mult Scler; 2008 Jun; 14(5):622-30. PubMed ID: 18424480
[TBL] [Abstract][Full Text] [Related]
6. IFN-beta-regulated genes show abnormal expression in therapy-naïve relapsing-remitting MS mononuclear cells: gene expression analysis employing all reported protein-protein interactions.
Yamaguchi KD; Ruderman DL; Croze E; Wagner TC; Velichko S; Reder AT; Salamon H
J Neuroimmunol; 2008 Mar; 195(1-2):116-20. PubMed ID: 18279974
[TBL] [Abstract][Full Text] [Related]
7. Effect of IFN-beta therapy on the frequency and function of CD4(+)CD25(+) regulatory T cells and Foxp3 gene expression in relapsing-remitting multiple sclerosis (RRMS): a preliminary study.
Namdar A; Nikbin B; Ghabaee M; Bayati A; Izad M
J Neuroimmunol; 2010 Jan; 218(1-2):120-4. PubMed ID: 19932513
[TBL] [Abstract][Full Text] [Related]
8. Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients.
Weinstock-Guttman B; Bhasi K; Badgett D; Tamaño-Blanco M; Minhas M; Feichter J; Patrick K; Munschauer F; Bakshi R; Ramanathan M
J Neuroimmunol; 2008 Dec; 205(1-2):113-25. PubMed ID: 18950872
[TBL] [Abstract][Full Text] [Related]
9. Effects of interferon-beta on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-beta treatment in patients with multiple sclerosis.
Wiesemann E; Deb M; Trebst C; Hemmer B; Stangel M; Windhagen A
Mult Scler; 2008 Mar; 14(2):166-76. PubMed ID: 17942524
[TBL] [Abstract][Full Text] [Related]
10. Decreased integrin gene expression in patients with MS responding to interferon-beta treatment.
Muraro PA; Liberati L; Bonanni L; Pantalone A; Caporale CM; Iarlori C; De Luca G; Farina D; Lugaresi A; Gambi D
J Neuroimmunol; 2004 May; 150(1-2):123-31. PubMed ID: 15081256
[TBL] [Abstract][Full Text] [Related]
11. Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice.
van der Voort LF; Kok A; Visser A; Oudejans CB; Caldano M; Gilli F; Bertolotto A; Polman CH; Killestein J
Mult Scler; 2009 Feb; 15(2):212-8. PubMed ID: 18805837
[TBL] [Abstract][Full Text] [Related]
12. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
[TBL] [Abstract][Full Text] [Related]
13. Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production.
Hedegaard CJ; Sellebjerg F; Krakauer M; Hesse D; Bendtzen K; Nielsen CH
Mult Scler; 2011 May; 17(5):567-77. PubMed ID: 21177756
[TBL] [Abstract][Full Text] [Related]
14. Dynamic T-lymphocyte chemokine receptor expression induced by interferon-beta therapy in multiple sclerosis.
Krakauer M; Sorensen PS; Khademi M; Olsson T; Sellebjerg F
Scand J Immunol; 2006 Aug; 64(2):155-63. PubMed ID: 16867161
[TBL] [Abstract][Full Text] [Related]
15. Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study.
Boz C; Oger J; Gibbs E; Grossberg SE;
Mult Scler; 2007 Nov; 13(9):1127-37. PubMed ID: 17967840
[TBL] [Abstract][Full Text] [Related]
16. Glypican 5 is an interferon-beta response gene: a replication study.
Cénit MD; Blanco-Kelly F; de las Heras V; Bartolomé M; de la Concha EG; Urcelay E; Arroyo R; Martínez A
Mult Scler; 2009 Aug; 15(8):913-7. PubMed ID: 19556317
[TBL] [Abstract][Full Text] [Related]
17. Regulation of matrix metalloproteinases and their inhibitors by interferon-beta: a longitudinal study in multiple sclerosis patients.
Bernal F; Elias B; Hartung HP; Kieseier BC
Mult Scler; 2009 Jun; 15(6):721-7. PubMed ID: 19383643
[TBL] [Abstract][Full Text] [Related]
18. Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-beta 1a, and high doses of immunoglobulins.
Sarchielli P; Zaffaroni M; Floridi A; Greco L; Candeliere A; Mattioni A; Tenaglia S; Di Filippo M; Calabresi P
Mult Scler; 2007 Apr; 13(3):313-31. PubMed ID: 17439900
[TBL] [Abstract][Full Text] [Related]
19. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity.
Hesse D; Sellebjerg F; Sorensen PS
Neurology; 2009 Aug; 73(5):372-7. PubMed ID: 19652141
[TBL] [Abstract][Full Text] [Related]
20. Breakthrough disease during interferon-[beta] therapy in MS: No signs of impaired biologic response.
Hesse D; Krakauer M; Lund H; Søndergaard HB; Langkilde A; Ryder LP; Sorensen PS; Sellebjerg F
Neurology; 2010 May; 74(18):1455-62. PubMed ID: 20439848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]